News

The U.S. Food and Drug Administration placed a clinical hold on the investigational new drug (IND) application for CTX001, an experimental therapy for the treatment of sickle cell disease, according to a statement by CRISPR Therapeutics and Vertex Pharmaceuticals. The hold on the clinical development of CTX001 will…

A significant proportion of children with sickle cell disease (SCD) are not receiving key recommended vaccines on time or at all, according to a new study examining pneumococcal and meningococcal vaccinations among children in Michigan. The study, “Pneumococcal and Meningococcal Vaccination among Michigan Children with Sickle Cell Disease,”…

Sickle cell trait (SCT) is not associated with an increased incidence of stroke, a study in African-American patients suggests. The study, “Association of Sickle Cell Trait With Ischemic Stroke Among African Americans: A Meta-analysis,” was published in the journal JAMA Neurology. Sickle cell trait occurs in…

The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…

The U.S. Food and Drug Administration recently accepted an investigational new drug (IND) application submitted by Bioverativ and Sangamo Therapeutics for BIVV003, a gene-edited cell therapy candidate for the treatment of sickle cell disease. BIVV003 uses a nonviral approach that uses zinc finger nuclease (ZFN) gene-editing technology to…